AGNARGENICA THERAPEUTICS LIMITED
Announcement history available from 1 August 2025
Fromto
| Date / Time | Title | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 14 Aug 2026, 03:32 | Notification of cessation of securities - AGN | Other | — | 06027 | |
| 27 July 2026, 19:13 | Investor Presentation - Techknow Conference | Presentations | — | 03026 | |
| 24 July 2026, 19:18 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 | |
| 16 July 2026, 18:27 | ARG007 Shows Significant Neuroprotection in Concussion Study | Company Update | MS | 11001 | |
| 11 June 2026, 18:33 | Investor Webinar | Presentations | — | 14014 | |
| 11 June 2026, 18:33 | Investor Presentation | Presentations | — | 03026 | |
| 11 June 2026, 18:33 | ARG007 (Xaranetide) Completes All Three FDA Requested Assays | Company Update | MS | 11001 | |
| 10 June 2026, 18:19 | WHO Confirms Xaranetide as INN for ARG-007 | Company Update | MS | 11001 | |
| 10 June 2026, 00:13 | Notification of cessation of securities - AGN | Other | — | 06027 | |
| 26 May 2026, 19:52 | Release of Securities from Voluntary Escrow | Securities Administration | — | 06009 | |
| 21 May 2026, 19:01 | IND Application Advanced With Successful Completion of Assay | Company Update | MS | 11001 | |
| 14 May 2026, 19:15 | Clinical Advisory Committee Established to Advance Phase 2b | Company Update | MS | 11001 | |
| 29 Apr 2026, 18:20 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19003, 19008 | |
| 16 Apr 2026, 19:15 | Investor Presentation - Ignite Conference | Presentations | — | 03026 | |
| 26 Mar 2026, 19:13 | Presentations at European Stroke Organisation Conference | Company Administration | MS | 12008 | |
| 17 Mar 2026, 19:19 | Argenica Receives $3.97m R&D Tax Incentive Cash Rebate | Periodic Reports | MS | 03014 | |
| 11 Feb 2026, 19:17 | Half Yearly Report and Accounts | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 5 Feb 2026, 19:23 | Investor Presentation - Euroz Hartleys Healthcare Conference | Presentations | — | 03026 | |
| 2 Feb 2026, 20:01 | Successful Applicaton for EMA Paediatric Waiver | Company Update | MS | 11001 | |
| 28 Jan 2026, 19:15 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19002, 19007 | |
| 3 Jan 2026, 03:53 | Final Director's Interest Notice | Director Interests | — | 02010 | |
| 29 Dec 2025, 19:27 | Non-Executive Chair Resignation | Company Administration | — | 12001, 12017 | |
| 11 Dec 2025, 20:11 | AI Analysis Reveals Efficacy In Severe Stroke Patients | Company Update | MS | 11001 | |
| 4 Dec 2025, 19:17 | Positive TNK Study Results Fulfil Key FDA Requirement | Company Update | MS | 11001 | |
| 25 Nov 2025, 20:16 | ARG-007 Efficacious Dose Validated in New Preclinical Study | Company Update | MS | 11001 | |
| 13 Nov 2025, 06:05 | Final Director's Interest Notice | Director Interests | — | 02010 | |
| 13 Nov 2025, 06:03 | Results of Annual General Meeting | Meetings & Governance | — | 08003 | |
| 13 Nov 2025, 03:53 | AGM Chair's Address & Presentation | Presentations | — | 03026, 15002 | |
| 13 Nov 2025, 03:49 | Non-Executive Director Retirement | Company Administration | — | 12001 | |
| 31 Oct 2025, 20:16 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19001, 19006 | |
| 21 Oct 2025, 20:04 | Investor Presentation - Cannacord Dug & Device Conference | Presentations | — | 03026 | |
| 21 Oct 2025, 00:16 | Notification regarding unquoted securities - AGN | Other | — | 06021 | |
| 15 Oct 2025, 19:28 | Phase 2 Trial Promising Improvements in Functional Outcomes | Company Update | MS | 11001 | |
| 14 Oct 2025, 01:09 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004, 16002 | |
| 24 Sept 2025, 20:49 | ASX Small Caps Conference Presentation | Presentations | — | 03026 | |
| 17 Sept 2025, 18:57 | Date of AGM & Closing Date for Director Nominations | Meetings & Governance | — | 08006, 12008 | |
| 4 Sept 2025, 18:17 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 3 Sept 2025, 19:37 | Investor Webinar | Company Administration | — | 12008 | |
| 3 Sept 2025, 19:35 | Investor Presentation | Presentations | — | 03026 | |
| 3 Sept 2025, 19:34 | Topline Phase 2 Trial Results of ARG-007 in AIS Patients | Company Update | MS | 09014, 11001 | |
| 1 Sept 2025, 19:01 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 29 Aug 2025, 03:06 | Appendix 4G & Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 29 Aug 2025, 03:05 | Appendix 4E & Annual Report to 30 June 2025 | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 14 Aug 2025, 19:08 | Argenica Receives IND Feedback From FDA | Company Update | MS | 11001 | |
| 8 Aug 2025, 19:11 | Bioshares Biotech Summit Presentation | Presentations | — | 03026 | |
| 6 Aug 2025, 18:15 | Argenica Appoints Vice President of Regulatory Affairs | Company Administration | — | 12008 |
1–46 of 46
1 / 1